NASDAQ:KYTX Kyverna Therapeutics (KYTX) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free KYTX Stock Alerts $15.47 -0.47 (-2.95%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$15.43▼$16.1650-Day Range$15.47▼$30.0852-Week Range$15.43▼$35.06Volume705,577 shsAverage Volume384,504 shsMarket Capitalization$667.07 millionP/E RatioN/ADividend YieldN/APrice Target$42.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsSocial Media Get Kyverna Therapeutics alerts: Email Address Kyverna Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside176.3% Upside$42.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.05Based on 4 Articles This WeekInsider TradingAcquiring Shares$9.90 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($3.26) to ($4.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.37 out of 5 starsMedical Sector490th out of 913 stocksBiological Products, Except Diagnostic Industry79th out of 154 stocks 4.5 Analyst's Opinion Consensus RatingKyverna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKyverna Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for KYTX. Previous Next 0.0 Dividend Strength Dividend YieldKyverna Therapeutics does not currently pay a dividend.Dividend GrowthKyverna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KYTX. Previous Next 1.6 News and Social Media Coverage News SentimentKyverna Therapeutics has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kyverna Therapeutics this week, compared to 4 articles on an average week.Search Interest5 people have searched for KYTX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kyverna Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,900,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsOnly 18.08% of the stock of Kyverna Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($3.26) to ($4.07) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Kyverna Therapeutics Stock (NASDAQ:KYTX)Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Read More KYTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KYTX Stock News HeadlinesApril 21, 2024 | americanbankingnews.comKyverna Therapeutics (NASDAQ:KYTX) Trading Down 2.8%April 20, 2024 | americanbankingnews.comKyverna Therapeutics (NASDAQ:KYTX) Sees Large Volume IncreaseApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 19, 2024 | americanbankingnews.comKyverna Therapeutics (NASDAQ:KYTX) Reaches New 1-Year Low at $21.13April 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kyverna Therapeutics on Promising KYV-101 Drug Efficacy and Safety DataApril 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kyverna Therapeutics on Promising KYV-101 Clinical AdvancesApril 11, 2024 | finance.yahoo.comKyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune DiseasesApril 11, 2024 | prnewswire.comKyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune DiseasesApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kyverna Therapeutics on Promising Early-Stage KYV-101 Results for MS TreatmentMarch 29, 2024 | finance.yahoo.comFirst-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in MedMarch 29, 2024 | prnewswire.comFirst-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in MedMarch 29, 2024 | markets.businessinsider.comBuy Recommendation: Kyverna Therapeutics’ Innovative Autoimmune Cell Therapy and Robust Pipeline Promise Market LeadershipMarch 27, 2024 | finance.yahoo.comKyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial ResultsMarch 14, 2024 | finance.yahoo.comWhy That Hot Biotech IPO Could Be a WinnerMarch 7, 2024 | markets.businessinsider.comKyverna, Stanford University To Evaluate KYV-101 In Non-Relapsing & Progressive Forms Of MSMarch 7, 2024 | finance.yahoo.comHow Kyverna is positioned for success on autoimmune therapy: CEOFebruary 27, 2024 | morningstar.comKyverna Therapeutics Inc KYTXFebruary 27, 2024 | investing.comKyverna Therapeutics Inc (KYTX)February 26, 2024 | msn.comEveryone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?February 26, 2024 | finance.yahoo.comKyverna Therapeutics Announces Pricing of Upsized Initial Public OfferingFebruary 26, 2024 | finance.yahoo.comKyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesSee More Headlines Receive KYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)6/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:KYTX Previous SymbolNASDAQ:KYTX CUSIPN/A CIK1994702 Webkyvernatx.com Phone510-626-8331FaxN/AEmployees96Year FoundedN/APrice Target and Rating Average Stock Price Target$42.75 High Stock Price Target$48.00 Low Stock Price Target$39.00 Potential Upside/Downside+176.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio3.05 Sales & Book Value Annual Sales$7.03 million Price / Sales94.88 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares43,115,000Free FloatN/AMarket Cap$666.99 million OptionableOptionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Peter Maag Ph.D. (Age 57)CEO & Director Comp: $709.99kMs. Karen Walker (Age 62)Chief Technology Officer Comp: $561.64kDr. James Chung M.D. (Age 56)Ph.D., Chief Medical Officer Comp: $645.62kDr. Tom Van Blarcom Ph.D.Senior VP & Head of ResearchMs. Portia SerameVice President of Human ResourcesDr. Dominic Borie M.D. (Age 61)Ph.D., President of Research & Development Mr. Devin MurraySenior Vice President of Partnerships & AlliancesMore ExecutivesKey CompetitorsREGENXBIONASDAQ:RGNXCARGO TherapeuticsNASDAQ:CRGXCullinan OncologyNASDAQ:CGEMMesoblastNASDAQ:MESORelay TherapeuticsNASDAQ:RLAYView All CompetitorsInsidersNorthpond Ventures Iii Gp, LlcBought 450,000 shares on 2/12/2024Total: $9.90 M ($22.00/share)View All Insider Transactions KYTX Stock Analysis - Frequently Asked Questions Should I buy or sell Kyverna Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kyverna Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KYTX shares. View KYTX analyst ratings or view top-rated stocks. What is Kyverna Therapeutics' stock price target for 2024? 5 Wall Street analysts have issued 12 month target prices for Kyverna Therapeutics' stock. Their KYTX share price targets range from $39.00 to $48.00. On average, they expect the company's stock price to reach $42.75 in the next year. This suggests a possible upside of 176.3% from the stock's current price. View analysts price targets for KYTX or view top-rated stocks among Wall Street analysts. How have KYTX shares performed in 2024? Kyverna Therapeutics' stock was trading at $30.10 at the beginning of the year. Since then, KYTX stock has decreased by 48.6% and is now trading at $15.47. View the best growth stocks for 2024 here. When is Kyverna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 25th 2024. View our KYTX earnings forecast. What ETF holds Kyverna Therapeutics' stock? iShares Neuroscience and Healthcare ETF holds 1,187 shares of KYTX stock, representing 0.66% of its portfolio. When did Kyverna Therapeutics IPO? Kyverna Therapeutics (KYTX) raised $319 million in an initial public offering (IPO) on Thursday, February 8th 2024. The company issued 14,500,000 shares at $22.00 per share. When did the company's quiet period expire? Kyverna Therapeutics' quiet period expired on Tuesday, March 19th. Kyverna Therapeutics had issued 14,500,000 shares in its initial public offering on February 8th. The total size of the offering was $319,000,000 based on an initial share price of $22.00. During the company's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Kyverna Therapeutics? Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KYTX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
